TaiDoc Technology Corporation Stocks

NT$ 126Last Updated 29.04.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

NT$ 382.09M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 126
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

TaiDoc Technology Corporation manufactures and markets medical devices worldwide. It offers In vitro diagnostics products, including blood glucose and multiple parameters monitoring systems, point of care testing devices, lancet and lancing devices, and vet health care products comprise blood glucose and calcium meters, and blood ketone meters; and medical devices, such as nebulizers, thermometers, blood pressure monitors, vital sign monitors, and pulse oximeters. The company also provides telehealth remote monitoring devices and smartphone applications; and Covid-19 antigen rapid test kits. In addition, it offers services for regulatory professionals, as well as in the areas of clinical suggestions, engineering resources, and manufacturing systems. TaiDoc Technology Corporation was founded in 1998 and is headquartered in New Taipei City, Taiwan.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, neutral on EV/E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks